이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Aldeyra Therapeutics 관리

관리 기준 확인 2/4

Aldeyra Therapeutics' CEO는 Todd Brady, Jan2012 에 임명되었습니다 의 임기는 12.42 년입니다. 총 연간 보상은 $ 3.68M, 15.8% 로 구성됩니다. 15.8% 급여 및 84.2% 보너스(회사 주식 및 옵션 포함). 는 $ 4.19M 가치에 해당하는 회사 주식의 1.94% 직접 소유합니다. 4.19M. 경영진과 이사회의 평균 재임 기간은 각각 3.4 년과 10.8 년입니다.

주요 정보

Todd Brady

최고 경영자

US$3.7m

총 보상

CEO 급여 비율	15.8%
CEO 임기	12.7yrs
CEO 소유권	1.9%
경영진 평균 재임 기간	3.7yrs
이사회 평균 재임 기간	11.1yrs

최근 관리 업데이트

Recent updates

Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment

Sep 14

Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization

Aug 04

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?

Aug 03

Aldeyra says trial for dry eye disease candidate reached key goals

Jul 12

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Apr 19

Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts

Feb 17

Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap

Dec 23

Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?

Dec 22

CEO 보상 분석

Todd Brady 의 보수는 Aldeyra Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$38m
Mar 31 2024	n/a	n/a	-US$30m
Dec 31 2023	US$4m	US$581k	-US$38m
Sep 30 2023	n/a	n/a	-US$46m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$61m
Dec 31 2022	US$3m	US$559k	-US$62m
Sep 30 2022	n/a	n/a	-US$65m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$63m
Dec 31 2021	US$3m	US$547k	-US$58m
Sep 30 2021	n/a	n/a	-US$53m
Jun 30 2021	n/a	n/a	-US$46m
Mar 31 2021	n/a	n/a	-US$39m
Dec 31 2020	US$2m	US$544k	-US$38m
Sep 30 2020	n/a	n/a	-US$39m
Jun 30 2020	n/a	n/a	-US$49m
Mar 31 2020	n/a	n/a	-US$55m
Dec 31 2019	US$4m	US$523k	-US$61m
Sep 30 2019	n/a	n/a	-US$58m
Jun 30 2019	n/a	n/a	-US$50m
Mar 31 2019	n/a	n/a	-US$46m
Dec 31 2018	US$3m	US$506k	-US$39m
Sep 30 2018	n/a	n/a	-US$35m
Jun 30 2018	n/a	n/a	-US$29m
Mar 31 2018	n/a	n/a	-US$26m
Dec 31 2017	US$2m	US$473k	-US$22m

보상 대 시장: Todd 의 총 보상 ($USD 3.68M )은 US 시장( $USD 1.62M ).

보상과 수익: 회사가 수익성이 없는 동안 Todd 의 보상이 증가했습니다.

CEO

Todd Brady (52 yo)

12.7yrs

테뉴어

US$3,684,651

보상

Dr. Todd C. Brady, M.D., Ph D., served as a Director at F-star Therapeutics, Inc from November 20, 2020 to March 2023. He has been the Chief Executive Officer and President of Aldeyra Therapeutics, Inc. si...

리더십 팀

이름	위치	테뉴어	보상	소유권
Todd Brady	CEO, President & Director	12.7yrs	US$3.68m	1.94% $ 6.4m
Stephen Machatha	Chief Development Officer	3.7yrs	US$1.59m	0.19% $ 614.7k
Michael Alfieri	Principal Financial & Accounting Officer	less than a year	데이터 없음	데이터 없음
David Burke	Head of Investor Relations	no data	데이터 없음	데이터 없음
Laura Nichols	Operations Manager	no data	데이터 없음	데이터 없음

3.7yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: ALDX 의 관리팀은 경험 ( 3.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Todd Brady	CEO, President & Director	19.7yrs	US$3.68m	1.94% $ 6.4m
Richard Douglas	Independent Chair of the Board	8yrs	US$221.98k	0.21% $ 687.5k
Ben Bronstein	Independent Director	14.3yrs	US$190.40k	0.048% $ 155.4k
Gary Phillips	Independent Director	15.3yrs	US$194.07k	0.025% $ 81.5k
Martin Joyce	Independent Director	10.9yrs	US$195.66k	0.040% $ 131.8k
Neal Walker	Independent Director	11.3yrs	US$174.22k	0.027% $ 87.2k
Jay Duker	Member of Retina Segment Scientific Advisory Board	no data	데이터 없음	데이터 없음
Paul Karpecki	Member of Anterior Segment Scientific Advisory Board	4.7yrs	데이터 없음	데이터 없음
John Sheppard	Member of Anterior Segment Scientific Advisory Board	no data	데이터 없음	데이터 없음
Nancy Miller-Rich	Independent Director	4.7yrs	US$174.22k	0% $ 0
Victor Perez	Member of Anterior Segment Scientific Advisory Board	no data	데이터 없음	데이터 없음
David Chu	Member of Anterior Segment Scientific Advisory Board	no data	데이터 없음	데이터 없음

11.1yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: ALDX 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.8 년).

Aldeyra Therapeutics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Chief Development Officer recently sold US$76k worth of stock

Chief Development Officer notifies of intention to sell stock

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

CEO, President & Director recently sold US$581k worth of stock

CEO, President & Director notifies of intention to sell stock

CEO, President & Director exercised options and sold US$492k worth of stock

Recent updates

Chief Development Officer recently sold US$76k worth of stock

Chief Development Officer notifies of intention to sell stock

Price target increased by 8.1% to US$10.00

New minor risk - Share price stability

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Consensus EPS estimates fall by 209%

New minor risk - Profitability

No longer forecast to breakeven

Aldeyra Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Consensus EPS estimates upgraded to US$0.18 loss

Forecast to breakeven in 2026

Consensus EPS estimates fall by 163%

Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

No longer forecast to breakeven

New minor risk - Profitability

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

New minor risk - Profitability

No longer forecast to breakeven

Forecast to breakeven in 2024

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

CEO, President & Director recently sold US$581k worth of stock

CEO, President & Director notifies of intention to sell stock

Forecast to breakeven in 2024

New minor risk - Profitability

Forecast to breakeven in 2024

Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?

Consensus revenue estimates increase by 55%

Consensus revenue estimates increase by 57%

Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis

Consensus revenue estimates increase by 600%

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Consensus revenue estimates decrease by 82%, EPS upgraded

Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?

New minor risk - Market cap size

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Update of U.S. Food and Drug Administration Relating to the New Drug Application for Reproxalap for the Treatment of the Signs and Symptoms of Dry Eye Disease

Consensus revenue estimates decrease by 61%, EPS upgraded

Price target decreased by 13% to US$17.86

CEO, President & Director exercised options and sold US$492k worth of stock

Frank R. Cruz Announces Securities Fraud Lawsuit Against Aldeyra Therapeutics, Inc

Consensus revenue estimates increase by 36%

Consensus revenue estimates decrease by 73%, EPS upgraded

Holzer & Holzer, LLC Files Class Action Lawsuit Against Aldeyra Therapeutics, Inc

Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX--629 in Patients with Chronic Cough

Consensus revenue estimates increase by 15%

Aldeyra Therapeutics, Inc. Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE--2 Trial of Reproxalap in Allergic Conjunctivitis

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 30, 2023

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates decrease by 41%, EPS upgraded

Price target increased by 8.4% to US$21.83

Aldeyra Therapeutics, Inc. Advances Investigational Oral RASP Modulator ADX--629 Into New Phase 2 Systemic Disease Trials

Aldeyra Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease

Forecast to breakeven in 2025

Insufficient new directors

Aldeyra Therapeutics, Inc. Submits New Drug Application to the U.S. Food and Drug Administration for Adx-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics, Inc. Announces Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial

Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA

Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Part 1 of Phase 3 Guard Trial of Adx-2191 in Proliferative Vitreoretinopathy

Aldeyra Therapeutics, Inc. Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA

Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment

Insider recently bought US$1.1m worth of stock